Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17

Paul E Goss, James N Ingle, Silvana Martino, Nicholas J Robert, Hyman B Muss, Martine J Piccart, Monica Castiglione, Dongsheng Tu, Lois E Shepherd, Kathleen I Pritchard, Robert B Livingston, Nancy E Davidson, Larry Norton, Edith A Perez, Jeffrey S Abrams, David A Cameron, Michael J Palmer, Joseph L Pater

Research output: Contribution to journalArticlepeer-review

Abstract

Most recurrences in women with breast cancer receiving 5 years of adjuvant tamoxifen occur after 5 years. The MA.17 trial, which was designed to determine whether extended adjuvant therapy with the aromatase inhibitor letrozole after tamoxifen reduces the risk of such late recurrences, was stopped early after an interim analysis showed that letrozole improved disease-free survival. This report presents updated findings from the trial.
Original languageEnglish
Pages (from-to)1262-71
Number of pages10
JournalJNCI: Journal of the National Cancer Institute
Volume97
Issue number17
DOIs
Publication statusPublished - 7 Sep 2005

Keywords

  • Aged
  • Antineoplastic Agents, Phytogenic
  • Antineoplastic Combined Chemotherapy Protocols
  • Aromatase Inhibitors
  • Breast Neoplasms
  • Chemotherapy, Adjuvant
  • Disease-Free Survival
  • Female
  • Humans
  • Incidence
  • Lymphatic Metastasis
  • Middle Aged
  • Nitriles
  • Postmenopause
  • Receptors, Estrogen
  • Receptors, Progesterone
  • Survival Analysis
  • Tamoxifen
  • Treatment Outcome
  • Triazoles

Fingerprint

Dive into the research topics of 'Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17'. Together they form a unique fingerprint.

Cite this